empty
 
 
id
Cari
Bantuan
Pembukaan akun instan
Platform Trading
Deposit/Penarikan
Cari
P2P Pertukaran Pasar Keuangan Untuk Kitra Forum Tentang perusahaan
id
Untuk Trader
Grafik
#AUPH

#AUPH (Aurinia Pharmaceuticals Inc). Nilai tukar dan grafik online.

#AMGN Kembali ke daftar instrumen #AZN

Konverter mata uang

Aurinia Pharmaceuticals Inc
8.27 USD
09 Jan 2025 22:59
Perubahan Harga (% chg)
$0
(0%)
Penutupan Sebelumnya
Penutupan Sebelumnya

Harga penutupan, hari sebelumnya.
$8.27
Buka
Buka

Harga pembukaan.
$8.34
Ketinggian Harian
Ketinggian Harian

Harga tertinggi pada hari transaksi terakhir.
$8.27
Kerendahan Harian
Kerendahan Harian

Harga terendah pada hari transaksi terakhir
$8.27
Kapitalisasi pasar
Kapitalisasi pasar

Nilai total perusahaan dalam pasar saham. Umumnya dihitung dengan menggandakan saham-saham yang beredang dengan harga saham saat itu.
$9.14
Saham Beredar
Saham Beredar

Jumlah saham yang dipegang oleh para investor dan insider perusahaan, diluar sekuritas dilutif (dilutive securities) seperti non-vested RSU dan unexercised options.
$8.27
Unduh arsip
Beli
8.27
Jual
8.27
Buka tabel dalam tampilan layar penuh
Beli
8.27
Jual
8.27
Unduh arsip
Buka tabel dalam tampilan layar penuh

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. is a Canadian biotech company specializing in the production of drugs against autoimmune diseases.

Aurinia Pharmaceuticals Inc. maintains cooperation with Japanese companies, particularly Otsuka Pharmaceutical Co.

The company’s market cap currently stands at $1.067 billion. Aurinia reported revenues of $45.6 million last year with a net loss of $180.97 million.

Aurinia Pharmaceuticals Inc. stock and what affects it

The stock is traded on the NASDAQ exchange under the ticker name of AUPH. There is no information about upcoming dividend payments.

The stock is currently trading between $7.4 and $7.7. Over the past year, the share price has fluctuated from $6.29 to $33.97.

When trading this asset, you should pay attention to the following:

  • Any negative events and news will be detrimental to the company.
  • The company's earnings strongly depend on the results of new product trials.
  • It is not recommended to allocate more than 5% of your investment portfolio to this stock.
  • This is a high-risk stock with fairly large returns of over 30%.

Tidak bisa bicara sekarang?
Tanyakan pertanyaan anda lewat chat.